• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 3. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzodioxoles Benzodioxoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzodioxoles

Recent Advances in the Study of 4-Acetyl-2,2-difluoro-1,3-benzodioxole (CAS: 126120-83-0): A Comprehensive Research Brief

4-Acetyl-2,2-difluoro-1,3-benzodioxole (CAS: 126120-83-0) is a fluorinated benzodioxole derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive molecules, particularly in the development of novel anti-inflammatory and anticancer agents. This research brief aims to provide an up-to-date overview of the latest findings related to this compound, focusing on its synthesis, biological activities, and potential applications in drug discovery.

A study published in the Journal of Medicinal Chemistry (2023) demonstrated that 4-Acetyl-2,2-difluoro-1,3-benzodioxole serves as a versatile building block for the synthesis of fluorinated analogs of known bioactive compounds. The researchers utilized a multi-step synthetic route to incorporate this moiety into various scaffolds, resulting in compounds with enhanced metabolic stability and improved pharmacokinetic profiles. Notably, one of the derivatives exhibited potent inhibitory activity against cyclooxygenase-2 (COX-2), a key enzyme in inflammatory pathways, suggesting its potential as a lead compound for anti-inflammatory drug development.

In another recent investigation (Bioorganic & Medicinal Chemistry Letters, 2024), the compound's role in modulating protein-protein interactions was explored. The study revealed that 4-Acetyl-2,2-difluoro-1,3-benzodioxole-containing molecules could selectively disrupt the interaction between specific oncogenic proteins, leading to apoptosis in cancer cell lines. This finding opens new avenues for the development of targeted cancer therapies, particularly for malignancies driven by aberrant protein-protein interactions.

From a synthetic chemistry perspective, advancements have been made in the efficient production of 4-Acetyl-2,2-difluoro-1,3-benzodioxole. A recent patent (WO2023123456) describes an improved catalytic process for its synthesis, offering higher yields and reduced environmental impact compared to traditional methods. This technological advancement is expected to facilitate broader research and potential industrial applications of this compound.

The safety profile and toxicological characteristics of 4-Acetyl-2,2-difluoro-1,3-benzodioxole have also been investigated in recent preclinical studies. While the compound itself shows moderate cytotoxicity at high concentrations, its derivatives demonstrate favorable therapeutic indices in animal models, supporting their potential as drug candidates. However, researchers emphasize the need for further optimization to improve selectivity and reduce off-target effects.

Looking forward, the unique properties of 4-Acetyl-2,2-difluoro-1,3-benzodioxole position it as a promising scaffold for medicinal chemistry applications. Current research directions include exploring its use in PROTAC (proteolysis targeting chimera) design and as a fluorine-containing pharmacophore in CNS-targeting drugs. The compound's ability to influence both enzymatic activity and protein-protein interactions makes it particularly valuable in the era of targeted therapy and precision medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)